FMS Stock Rides on Diversified Portfolio and Restructuring Initiatives

Zacks10-03

Fresenius Medical Care FMS is one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure. Through its network of more than 3,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2472112618?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/n60QxYnwUpNYHrw1xbieiQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/62f2ca75152a3979f64affaf3050aa9a","is_english":true,"pubTime":"2024-10-03 19:06","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2472112618","market":"us","top_or_hot":-1,"title":"FMS Stock Rides on Diversified Portfolio and Restructuring Initiatives","media":"Zacks","content":"<div>\n<p>Fresenius Medical Care FMS is one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure. Through its network of more than 3,...</p>\n\n<a href=\"https://finance.yahoo.com/news/fms-stock-rides-diversified-portfolio-110600734.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FMS Stock Rides on Diversified Portfolio and Restructuring Initiatives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFMS Stock Rides on Diversified Portfolio and Restructuring Initiatives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-03 19:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/fms-stock-rides-diversified-portfolio-110600734.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Fresenius Medical Care FMS is one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure. Through its network of more than 3,...</p>\n\n<a href=\"https://finance.yahoo.com/news/fms-stock-rides-diversified-portfolio-110600734.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://finance.yahoo.com/news/fms-stock-rides-diversified-portfolio-110600734.html","article_id":"2472112618","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/n60QxYnwUpNYHrw1xbieiQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/62f2ca75152a3979f64affaf3050aa9a"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2472112618","pubTimestamp":1727953560,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Fresenius Medical Care FMS is one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure. Through its network of more than 3,600 clinics across the world, the company offers dialysis services and products in more than 120 countries and employs over 109,000 staff in more than 50 countries.Fresenius Medical reports through two segments — Care Delivery and Care Enablement. The Care Delivery segment consists of the company’s Dialysis Services and the Care-Coordination , which accounted for 79.6% of net revenues in the first half of 2024. The Care Enablement segment comprises the company’s Dialysis machines, dialyzers, dialysis solutions, hemodialysis concentrates, bloodline systems, water treatment systems, dialysis drugs and other medical products. The segment accounted for 20.4% of net revenues in the same period.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","BK4504":"桥水持仓","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","BK4185":"保健护理机构","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","DGX":"奎斯特诊疗","BK4583":"猴痘概念","FMS":"费森尤斯医疗","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU1303367103.USD":"摩根大通多经理另类基金 A (acc)","BAX":"百特国际","LU2098885051.SGD":"JPMorgan Funds - Multi-Manager Alternatives A (acc) SGD","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","UHS":"Universal Health Services Inc Cl","BK4196":"保健护理服务","BK4082":"医疗保健设备"},"translate_title":"FMS股票依赖于多元化投资组合和重组举措","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FMS":1,"UHS":1,"DGX":1,"BAX":0.9},"content_text":"Fresenius Medical Care FMS is one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure. Through its network of more than 3,600 clinics across the world, the company offers dialysis services and products in more than 120 countries and employs over 109,000 staff in more than 50 countries.\nFresenius Medical reports through two segments — Care Delivery and Care Enablement. The Care Delivery segment consists of the company’s Dialysis Services and the Care-Coordination (non-dialysis laboratory services), which accounted for 79.6% of net revenues in the first half of 2024. The Care Enablement segment comprises the company’s Dialysis machines, dialyzers, dialysis solutions, hemodialysis concentrates, bloodline systems, water treatment systems, dialysis drugs and other medical products. The segment accounted for 20.4% of net revenues in the same period.\nFMS’ quarterly results are likely to continue benefiting from improving treatment volumes as well as a stabilizing labor environment in the United States. Overall price improvements also supported growth in the Care Enablement segment. Meanwhile, FMS’ newly implemented operating model led to operational improvements. The company’s divestment of its noncore and dilutive assets looks promising as they will help it focus on its core and growing categories as well as boost its cash resources.\nThe company’s shares have risen 1.5% year to date compared with the industry’s 8.4% growth. The stock was primarily driven by top-line growth in the past couple of quarters. The S&P 500 Index was up 20% in the same time frame.\nImage Source: Zacks Investment Research\nHowever, U.S. revenues continued to be hurt by FX impact. The bottom line was hurt by inflationary cost increases in energy, material and personnel.\nDiversified Product Portfolio Boosts FMS’ Prospects\nFresenius Medical offers a wide array of Hemodialysis, Peritoneal dialysis and Acute dialysis products. To further boost the quality of life for its patients and increase their choice of available treatment options, Fresenius Medical Care remains focused on further expanding its home dialysis offerings. In 2022, the company provided around 15% of its dialysis treatments in the United States in a home setting, the same as last year. By 2025, the company has set a goal to perform 25% of all treatments in the U.S. at a patient’s home.\nFMS’ Strong Global Foothold Buoys Optimism\nFresenius Medical has a solid market hold in the regions of North America, Europe (EMEA), Asia Pacific and Latin America. To strengthen its market position, the company is resorting to various approaches, like enhancing its organic growth and making strategic and suitable acquisitions. The company also aims to align its business activities through public-private partnerships in the dialysis business for tapping into new markets in the coming quarters. In the recent past, the company entered the dialysis services market in Israel.\nFresenius Medical also expanded its dialysis services business in India by acquiring an 85% stake in Sandor Nephro Services, a dialysis group, offering dialysis treatment and other associated services, such as laboratory tests, to 308,471 patients in 3,624 dialysis clinics worldwide. In the second quarter of 2024, it witnessed strong contributions from the Asia Pacific, EMEA and Latin America, respectively.\nRestructuring Initiatives Driving Savings\nIn October 2020, Fresenius Medical unveiled its 2025 strategy at its Capital Markets Day. This strategy is an appropriate one as it prioritizes patients' needs, and the quality of care is in line with key drivers and developments for its industry. This positions Fresenius Medical’s business well to deliver sustainable growth over the medium term and further. The FME25 transformation is anticipated to achieve a substantial amount of savings by 2025.\nThe company continues to progress with its FME25 transformation. In the second quarter, FMS generated 57 million euros in savings by implementing initiatives under its FME25 transformation program. The company targets savings in the range of 250-300 million euros by 2024-end and 650 million euros by 2025-end.\nFactors Hurting FMS Stock\nFresenius Medical has numerous competitors in the field of health care services as well as the sale of dialysis products. Tough competition in the niche markets is likely to impede the company’s sales opportunities and lose market share. However, per management, concerns that arise due to competition represent a low risk for the company in the short and mid-term. The company faces aggressive rivalry from HCA Holdings, DaVita HealthCare and Baxter International.\nFMS faces a highly regulated environment in almost every country in which it operates. Furthermore, the company has to fulfill specific legal requirements everywhere, including the tough antitrust regulations. Violating healthcare or other regulations under public law can result in extensive legal repercussions.\n\nFresenius Medical Care AG & Co. KGaA Price\n\nFresenius Medical Care AG & Co. KGaA price | Fresenius Medical Care AG & Co. KGaA Quote\n\nZacks Rank & Stock to Consider\nFresenius Medical Care currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks in the broader medical space are Universal Health Service UHS, Quest Diagnostics DGX and Baxter International BAX, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nUniversal Health Service has an estimated long-term growth rate of 19%. UHS’ earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.\nUniversal Health Service has gained 47% compared with the industry's 47.7% rise so far this year.\nQuest Diagnostics has an estimated long-term growth rate of 6.2%. DGX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.\nQuest Diagnostics shares have gained 12.3% so far this year compared with the industry’s 19% rise.\nBaxter’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 3.74%.\nBAX’s shares have declined 6.9% so far this year against the industry’s 13.3% growth.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nQuest Diagnostics Incorporated (DGX) : Free Stock Analysis Report\nUniversal Health Services, Inc. (UHS) : Free Stock Analysis Report\nBaxter International Inc. (BAX) : Free Stock Analysis Report\nFresenius Medical Care AG & Co. KGaA (FMS) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.0","shortVersion":"4.29.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2472112618"}